Dianthus Therapeutics: T. Rowe Price reports 10.5%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Dianthus Therapeutics, Inc. (DNTH) common stock is the subject of an amended ownership report by T. Rowe Price Investment Management, Inc. The reporting person reported beneficial ownership of 5,885,888 shares, or 10.5%, as of September 30, 2026, while expressly denying that the report is an admission of beneficial ownership.
Key Figures
Key Terms
beneficial ownership financial
sole voting power financial
sole dispositive power financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.